Examinando por Autor "Noriega, Viviana"

Mostrando 1 - 4 de 4
  • Miniatura
    Ítem
    The Antinociceptive Activities of Certain NSAIDS Combinations in Murine Orofacial Test
    (Thieme, 2020) Miranda, Hugo F.; Noriega, Viviana; Sierralta, Fernando; Sotomayor-Zárate, Ramón; Prieto, Juan Carlos
    Pain models are mostly in rodents and between them formalin orofacial test allow discrimination among antinociception and anti-inflammation. This assay use a formalin solution injected into the upper right lip of each mouse which produces two periods of pain separated by an inactive period. The aims of the present study were to evaluate, by means of the isobolographic analysis, the antinociception and anti-inflammatory activities of the following NSAIDs: dexketoprofen, diclofenac, piroxicam and metamizole in an orofacial. The NSAIDs administered intraperitoneally produced a dose-dependent activity with the following order of potency of the rubbing behavior, in phase I: diclofenac > dexketoprofen > piroxicam > metamizole and in the phase II: metamizole > diclofenac > piroxicam > dexketoprofen. The coadministration of NSAIDs resulted in a synergistic interaction, which according to the value of the potency of the combination (II) presents the following range: dexketoprofen plus metamizole > dexketoprofen plus diclofenac > dexketoprofen plus piroxicam, in phase I and dexketoprofen plus metamizole > dexketoprofen plus piroxicam > dexketoprofen plus diclofenac, on the phase II. Data obtained in this work corroborate that NSAIDs alone or in combination inducing activities by additional mechanism of action supplementary to inhibition of COXs. This fact represent a novel approach that could be used as multimodal management of orofacial pain, since with this treatment strategies, by the reduction of doses, can help to diminish side effects of other dugs such opioids.
  • Miniatura
    Ítem
    El caso de aducanumab ¿Más esperanza que ciencia?
    (Pontificia Universidad Católica De Chile, 2021) Sánchez-Montoya, Eliana; Andresen, Max; Corrales, Raúl; Gallardo, Jorge; Noriega, Viviana; Weinstein-Oppenheimer, Caroline R.
    En junio, la Agencia de Alimentos y medicamentos de los Estados Unidos (FDA) otorgó aprobación mediante vía acelerada al medicamento aducanumab, desarrollado por Biogen, Inc. para tratamiento de la enfermedad de Alzheimer (EA). Esta autorización no ha estado exenta de controversia, ya que no se basó en un criterio de beneficio clínico demostrado, sino en un resultado de valoración sustituto, como es la reducción de la placa β-amieloide (Aβ). Primero con mecanismo novedoso aprobado para EA desde 2003 (Jaffe, 2021).
  • Miniatura
    Ítem
    Involvement of NO in Antinociception of NSAIDS in Murine Formalin Hind Paw Assay
    (Thieme, 2020) Noriega, Viviana; Miranda, Hugo F.; Prieto, Juan Carlos; Sotomayor-Zárate, Ramón; Sierralta, Fernando
    There are different animal models to evaluate pain among them the formalin hind paw assay which is widely used since some of its events appear to be similar to the clinical pain of humans. The assay in which a dilute solution of formalin is injected into the dorsal hindpaw of a murine produces two ‘phases’ of pain behavior separated by a inactive period. The early phase (Phase I) is probably due to direct activation of nociceptors and the second phase (Phase II) is due to ongoing inflammatory input and central sensitization. Mice were used to determine the potency antinociceptive of piroxicam (1,3,10,and 30 mg/kg), parecoxib (0.3, 1,3,10 and 30 mg/kg), dexketoprofen (3,10,30 and 100 mg/kg) and ketoprofen (3,10,30 and 100 mg/kg). Doseresponse for each NSAIDs were created before and after 5 mg/kg of LNAME i.p. or 5 mg/kg i.p. of 7nitroindazole. A leastsquares linear regression analysis of the log dose–response curves allowed the calculation of the dose that produced 50 % of antinociception (ED50) for each drug. The ED50 demonstrated the following rank order of potency, in the phase I: piroxicam > dexketoprofen > ketoprofen > parecoxib and in the phase II: piroxicam > ketoprofen > parecoxib > dexketoprofen. Pretreatment of the mice with LNAME or 7nitroindazol induced a significant increase of the analgesic power of the NSAIDs, with a significant reduction of the ED50. It is suggested that NO may be involved in both phases of the trial, which means that nitric oxide regulates the bioactivity of NSAIDs.
  • Miniatura
    Ítem
    Receptors involved in dexketoprofen analgesia in murine visceral pain
    (Indian Academy of Sciences, 2020-07-02) Noriega, Viviana; Sierralta, Fernando; Poblete, P.; Aranda, N.; Sotomayor-Zárate, Ramón; Prieto, Juan Carlos; Miranda, H. F.
    Various animal models, especially rodents, are used to study pain, due to the difficulty of studying it in humans. Many drugs that produce analgesia have been studied and there is evidence among which NSAIDs deserve to be highlighted. Dexketoprofen (DEX) provides a broad antinociceptive profile in different types of pain; therefore, this study was designed to evaluate the profile of antinociceptive potency in mice. Analgesic activity was evaluated using the acetic acid abdominal constriction test (writhing test), a chemical model of visceral pain. Dose-response curves for i.p. DEX administration (1, 3, 10, 30 and 100 mg/kg), using at least six mice in each of at least five doses, was obtained before and 30 min after pre-treatment with different pharmacological agents. Pretreatment of the mice with opioid receptor antagonists was not effective; however, the serotonin receptor antagonist and nitric oxide synthase inhibitor produce a significant increase in DEX-induced antinociception. The data from the present study shows that DEX produces antinociception in the chemical twisting test of mice, which is explained with difficulty by the simple inhibition of COX. This effect appears to be mediated by other mechanisms in which the contribution of the NO and 5-HT pathways has an important effect on DEXinduced antinociception.